Evidence map›Paper›PMID 35886075›Full record

ArticleGenes2022

Identification of New Toxicity Mechanisms in Drug-Induced Liver Injury through Systems Pharmacology.

Aurelio A Moya-García, Andrés González-Jiménez, Fernando Moreno, Camilla Stephens, María Isabel Lucena, Juan A G Ranea

Open access · goldAbstract read
In one paragraph

Article in Genes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Aurelio A Moya-GarcíaDepartamento de Biología Molecular y Bioquímica, Universidad de Málaga, 29071 Málaga, Spain.ORCID 0000-0002-0567-0949
Andrés González-JiménezInstituto de Investigación Biomédica de Málaga (IBIMA), 29590 Málaga, Spain.
Fernando MorenoDepartamento de Arquitectura de Computadores, Universidad de Málaga, 29071 Málaga, Spain.ORCID 0000-0001-7498-1962
Camilla StephensInstituto de Investigación Biomédica de Málaga (IBIMA), 29590 Málaga, Spain.
María Isabel LucenaInstituto de Investigación Biomédica de Málaga (IBIMA), 29590 Málaga, Spain.ORCID 0000-0001-9586-4896
Juan A G RaneaDepartamento de Biología Molecular y Bioquímica, Universidad de Málaga, 29071 Málaga, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas · ESCentre for Biomedical Network Research on Rare Diseases · ESHospital Clínico Universitario Virgen de la Victoria · ESInstituto de Investigación Biomédica de Málaga · ESUniversidad de Málaga · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Among adverse drug reactions, drug-induced liver injury presents particular challenges because of its complexity, and the underlying mechanisms are still not completely characterized. Our knowledge of the topic is limited and based on the assumption that a drug acts on one molecular target. We have leveraged drug polypharmacology, i.e., the ability of a drug to bind multiple targets and thus perturb several biological processes, to develop a systems pharmacology platform that integrates all drug-target interactions. Our analysis sheds light on the molecular mechanisms of drugs involved in drug-induced liver injury and provides new hypotheses to study this phenomenon.

Indexed as

Chemical and Drug Induced Liver InjuryDrug-Related Side Effects and Adverse ReactionsHumansNetwork PharmacologyPolypharmacologydrug-induced liver injurypolypharmacologysystems pharmacologytoxicology

Identifiers

PMID35886075
PMCPMC9315637
OpenAlexW4286433302

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.